David E Crawford, David Albala, Marc B Garnick, Andrew W Hahn, Paul Maroni, Rana R McKay, Martin Miner, Peter Orio Ⅲ, Kshitij Pandit, Scott Sellinger, Evan Y Yu, Robert H Eckel
INTRODUCTION: Risk of cardiovascular disease is higher among men with prostate cancer than men without, and prostate cancer treatments (especially those that are hormonally based) are associated with increased cardiovascular risk. MATERIALS AND METHODS: An 11-member panel of urologic, medical, and radiation oncologists (along with a men's health specialist and an endocrinologist/preventive cardiologist) met to discuss current practices and challenges in the management of cardiovascular risk in prostate cancer patients who are taking androgen deprivation therapies (ADT) including LHRH analogues, alone and in combination with androgen-targeted therapies (ATTs)...
April 2024: Canadian Journal of Urology